GLG 801

Drug Profile

GLG 801

Alternative Names: GLG-801

Latest Information Update: 04 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute
  • Developer GLG Pharma
  • Class Antineoplastics; Small molecules; Urologics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Preclinical Polycystic kidney disease

Most Recent Events

  • 20 Nov 2015 Phase-II clinical trials in Chronic lymphocytic leukaemia (Combination therapy) in Poland (PO) prior to November 2015
  • 20 Nov 2015 Preclinical trials in Polycystic kidney disease in Poland (unspecified) prior to November 2015
  • 20 Nov 2015 GLG Pharma plans phase I trials for Polycystic kidney disease in Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top